JanOne Completes Pre-IND Meeting with FDA on Jan123
April 18, 2023
LAS VEGAS, April 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regarding Jan123. Jan123 is the company's unique oral delivery of low dose naltrexone formulated to treat complex regional pain syndrome, an... READ MORE
April 13, 2023
LAS VEGAS, April 13, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Saturday, April 15th on the topic of Innovation in Pain Medicine and will be discussing the drug development programs at... READ MORE
JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market
March 24, 2023
LAS VEGAS, March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company's common stock at a purchase price... READ MORE
JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses
March 22, 2023
Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments LAS VEGAS, March 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced that on March 9, 2023 they entered into a Stock Purchase Agreement with... READ MORE
February 22, 2023
JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year" LAS VEGAS, Feb. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present data on two of its investigational pharmaceutical compounds... READ MORE
JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management
January 26, 2023
In meetings hosted by Nasdaq MarketSite, the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. LAS VEGAS, January 26, 2023 – JanOne (Nasdaq: JAN), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk... READ MORE
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC
January 10, 2023
The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a... READ MORE
JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC
September 22, 2022
The acquisition of Soin will provide JanOne with its second clinical stage product LAS VEGAS, Sept. 16, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has executed a term sheet to acquire Soin Therapeutics LLC and its product,... READ MORE
JanOne Inc. Announces an Improved Formulation of JAN101
June 28, 2022
Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 LAS VEGAS, June 28, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of... READ MORE
Optimized by Seraphinite Accelerator